Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. (LH) disclosed a new Form 3 for director Victor Bulto Carulla, indicating his status as a board member and initial ownership position. The filing states that no securities are beneficially owned at this time, meaning he currently reports no direct or indirect holdings of Labcorp stock or derivative securities.
Labcorp Holdings Inc. reported that its Board of Directors has appointed Victor Bulto as a new board member, effective December 1, 2025. He will receive director compensation consistent with Labcorp’s existing director compensation program described in its most recent proxy statement.
Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, roles he has held since April 2022. Over more than two decades at Novartis, he has led major therapeutic franchises and regional businesses, including U.S. Pharmaceuticals and European neuroscience. Labcorp later issued a press release announcing his appointment and filed it as an exhibit, highlighting his extensive pharmaceutical and leadership background.
Labcorp (LH) reported an insider transaction by President & CEO and Director Adam H. Schechter. On 11/11/2025, he sold 5,745 shares of common stock at $262.75 per share, as disclosed on Form 4.
The transaction was made pursuant to a Rule 10b5-1 trading plan. Following the sale, Schechter beneficially owns 87,574 shares, held directly.
Laboratory Corporation of America Holdings (LH) reported a Form 144 notice of a proposed sale of 5,745 common shares, with an aggregate market value of $1,509,498.75. The filing lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 11/11/2025, and the NYSE as the exchange. Shares outstanding were 82,900,000.
The shares to be sold were acquired through restricted stock vesting on 02/02/2024 (1,911 shares), 02/07/2024 (2,101 shares), and 02/11/2024 (1,733 shares). The filing also shows a recent transaction by a named seller: Adam H. Schechter sold 5,643 shares on 08/11/2025 for $1,505,439.54 in gross proceeds.
Labcorp (LH) Form 4: EVP, President of Central Labs & International Megan D. Bailey reported equity transactions. On 11/01/2025, 370 shares of Common Stock were acquired (code M) from Restricted Stock Units. On 11/03/2025, 179 shares were surrendered (code F) at $257.84 to satisfy tax withholding.
Following these transactions, direct ownership stands at 3,594 Common Stock shares. Derivative holdings include 2,599 Restricted Stock Units that vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider equity update by EVP, CIO & CTO Akinbolade Oyegunwa. On 11/01/2025, 370 shares of common stock were acquired via the conversion of Restricted Stock Units (code M). On 11/03/2025, 107 shares were withheld to cover taxes at $257.84 per share (code F). Following these transactions, direct holdings are 3,727.253 shares.
The filing notes 1,939 Restricted Stock Units remain outstanding. These RSUs vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider transaction by Director Richelle P. Parham. On 10/31/2025, she executed a sale (Transaction Code S) of 7,009 shares of common stock at an average price of $254.2835 per share. Following the sale, she beneficially owns 2,469 shares, held directly.
The filing was signed by an attorney-in-fact on 11/04/2025.
LH filed a Form 144 notice for a proposed sale of 7,009 shares of common stock on the NYSE, with an approximate sale date of 10/31/2025. The filing lists an aggregate market value of $1,782,273.05 for the proposed sale and names Fidelity Brokerage Services LLC as broker. Shares outstanding were 82,900,000.
The shares to be sold were acquired through restricted stock vesting from 2018 through 2025, including tranches such as 1,263 (02/07/2018), 1,227 (02/12/2020), 986 (02/04/2021), 947 (02/07/2024), and 944 (02/06/2025), summing to 7,009 shares.
Labcorp Holdings Inc. reported stronger Q3 results. Revenue rose to $3,563.5 million from $3,282.0 million a year ago, and diluted EPS increased to $3.12 from $2.00 as operating income improved to $396.6 million. Diagnostics contributed about 78% of revenue and Biopharma Laboratory Services about 22%.
Year to date, revenue reached $10,435.9 million with net earnings attributable to Labcorp of $711.8 million. Cash from operations was strong at $1,026.3 million, supporting capital spending and portfolio moves. The company deployed $324.0 million on acquisitions and repurchased 0.9 million shares for $225.0 million at an average of $249.27. A quarterly dividend of $0.72 per share continued.
Balance sheet highlights show cash of $598.1 million, total assets of $18,261.6 million, and total debt of $5,582.4 million including the current portion. The accounts receivable securitization facility was increased to $700.0 million with $525.0 million outstanding. The company also announced agreements to acquire CHS outreach assets for approximately $195.0 million and Empire City Laboratories for up to $250.0 million, pending approvals.
Labcorp Holdings Inc. filed a current report to furnish a press release announcing its 2025 third quarter results. The filing identifies a press release dated October 28, 2025, titled “Labcorp Announces 2025 Third Quarter Results” as an exhibit, indicating the company has publicly shared its Q3 2025 performance details through that document.
The company lists its common stock, par value $0.10 per share, as trading on the New York Stock Exchange under the symbol LH. The report is signed on behalf of Labcorp by Executive Vice President and Chief Legal Officer Sandra D. van der Vaart.